Inappropriate Secretion of Follicle-Stimulating Hormone and Luteinizing Hormone in Polycystic Ovarian Disease

Yen, S. S. C.; Vela, Patricio A.; Rankin, Joel S.

doi:10.1210/jcem-30-4-435

Cited by 372 publications

(122 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One of the characteristic features of PCOD is high LH with low or normal FSH [13,14]. This discordant gonadotropin secretion in PCOD women has long been speculated to be produced by selective inhibition of FSH release presumably by increased inhibin [15,16].…”

Section: Discussionmentioning

confidence: 99%

Serum Immunoreactive Inhibin Levels in Polycystic Ovarian Disease (PCOD) and Hypogonadotropic Amenorrhea.

et al. 1994

View full text Add to dashboard Cite

Abstract. To evaluate the physiological significance of inhibin in various types of amenorrhea, serum immunoreactive (IR)-inhibin levels were measured and compared with those in normal cycling women. Amenorrheic women were as follows: (1) 23 women with PCOD, 11 women with hypogonadotropic amenorrhea (HA, n=23) and 11 women with regular menstrual cycles. Women with HA were further divided into 2 groups according to the presence or absence of withdrawal bleeding (WDB) after progesterone administration.HA with WDB was categorized as HA1, while HA without as HA 2. Serum IRinhibin levels in women with PCOD were significantly higher than those in HA 2 and normal women at days 2 to 5 from the onset of menstruation and significantly lower than those in normal women in the mid-luteal phase. A significant positive correlation was obtained between IR-inhibin and FSH in HA 2 (r=0.681) and HA 1 (r=0.658), but no significant correlation between these two hormones in PCOD and normal women. These results indicated that basal IR-inhibin levels vary with types of amenorrhea. High IR-inhibin levels in PCOD patients suggest that inhibin plays a part in the discordant gonadotropin secretion in these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Immunoreactive Inhibin Levels in Polycystic Ovarian Disease (PCOD) and Hypogonadotropic Amenorrhea.

et al. 1994

View full text Add to dashboard Cite

show abstract

“…LH hypersecretion -both basally and in response to GnRH administration -is a characteristic hallmark of PCOS (Yen et al, 1970;Barnes et al, 1989). This phenomenon has been considered to be the primary abnormality in classic PCOS and thus, the cause of androgen excess.…”

Section: Neuroendocrine Defectmentioning

confidence: 99%

The pathophysiology of polycystic ovary syndrome

Tsilchorozidou

Overton

Conway

2003

Clinical Endocrinology

232

167

View full text Add to dashboard Cite

“…Thus, for example, the etiology of anovulation in PCOS is multifactorial and includes alterations in ovarian, hypothalamic and pituitary function. Most women with PCOS have elevated plasma concentrations of luteinizing hormone (LH) and normal or decreased serum levels of follicle-stimulating hormone (FSH) 73 . The LH-enriched milieu promotes thecal steroidogenesis and thus contributes to the hyperandrogenism typically seen with this disorder.…”

Section: Pathophysiology Of Pcosmentioning

confidence: 99%

Statins in the Treatment of Polycystic Ovary Syndrome

Kodaman

Dulęba²

2008

Semin Reprod Med

View full text Add to dashboard Cite

Many women of reproductive age are affected by polycystic ovary syndrome (PCOS), a heterogeneous endocrinopathy characterized by androgen excess, chronic oligo-anovulation and/or polycystic ovarian morphology. In addition, PCOS is often associated with insulin resistance, systemic inflammation and oxidative stress which, on one hand, lead to endothelial dysfunction and dyslipidemia with subsequent cardiovascular sequelae and, on the other hand, to hyperplasia of the ovarian theca compartment with resultant hyperandrogenism and anovulation. While traditionally statins have been used to treat dyslipidemia by blocking HMG-CoA reductase, the rate limiting step in cholesterol biosynthesis; in fact, they possess pleiotropic actions, resulting in antioxidant, antiinflammatory and anti-proliferative effects. Statins offer a novel therapeutic approach to PCOS in that they address the dyslipidemia associated with the syndrome, as well as hyperandrogenism/ hyperandrogenemia. These actions may be due to an inhibition of the effects of systemic inflammation and insulin resistance/hyperinsulinemia. Evidence to date, both in vitro and in vivo, suggests that statins have potential in the treatment of PCOS; however, further clinical trials are needed before they can be considered a standard of care in the medical management of this common endocrinopathy.

show abstract

Inappropriate Secretion of Follicle-Stimulating Hormone and Luteinizing Hormone in Polycystic Ovarian Disease

Cited by 372 publications

References 0 publications

Serum Immunoreactive Inhibin Levels in Polycystic Ovarian Disease (PCOD) and Hypogonadotropic Amenorrhea.

Serum Immunoreactive Inhibin Levels in Polycystic Ovarian Disease (PCOD) and Hypogonadotropic Amenorrhea.

The pathophysiology of polycystic ovary syndrome

Statins in the Treatment of Polycystic Ovary Syndrome

Contact Info

Product

Resources

About